Fig. 1: Study design, clinical characteristics, and whole exome sequencing summary results of the relapsed small cell lung cancer discovery cohort.
From: Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
a Schematic representation of the clinical trial of combination immune checkpoint blockade (PD-L1 inhibitor plus PARP inhibitor) and sample analysis. Tumor samples were collected prior to treatment and analyzed using whole exome sequencing, RNA sequencing, digital spatial profiling, and immunohistochemistry. T-cell receptor sequencing was performed on pre- and on-treatment blood samples, and on select tumors, where available. b Swimmer plot indicating response and length of time on therapy for individual patients. Timing of responses are also indicated. c Heatmap summarizing mutation burden, mutational signatures, somatic variants and copy number alterations derived from whole exome sequencing of patient tumors. Smoking status and best response for each patient are also shown. Source data are provided as a Source Data file.
